A Single-arm, Multicenter, Phase II Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Progressed on Camrelizumab Combined With Apatinib
Latest Information Update: 23 May 2025
At a glance
- Drugs Cadonilimab (Primary) ; Regorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 15 May 2025 Status changed from not yet recruiting to recruiting.
- 04 Mar 2024 New trial record